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Abstract
Background: An absence of reliable molecular markers has hampered individualised breast cancer treatments, and a
major limitation for translational research is the lack of fresh tissue. There are, however, abundant banks of formalin-
fixed paraffin-embedded (FFPE) tissue. This study evaluated two platforms available for the analysis of DNA copy
number and gene expression using FFPE samples.
Methods: The cDNA-mediated annealing, selection, extension, and ligation assay (DASL™) has been developed for
gene expression analysis and the Molecular Inversion Probes assay (Oncoscan™), were used for copy number analysis
using FFPE tissues. Gene expression and copy number were evaluated in core-biopsy samples from patients with
breast cancer undergoing neoadjuvant chemotherapy (NAC).
Results: Forty-three core-biopsies were evaluated and characteristic copy number changes in breast cancers, gains in
1q, 8q, 11q, 17q and 20q and losses in 6q, 8p, 13q and 16q, were confirmed. Regions that frequently exhibited gains in
tumours showing a pathological complete response (pCR) to NAC were 1q (55%), 8q (40%) and 17q (40%), whereas
11q11 (37%) gain was the most frequent change in non-pCR tumours. Gains associated with poor survival were 11q13
(62%), 8q24 (54%) and 20q (47%). Gene expression assessed by DASL correlated with immunohistochemistry (IHC)
analysis for oestrogen receptor (ER) [area under the curve (AUC) = 0.95], progesterone receptor (PR)(AUC = 0.90) and
human epidermal growth factor type-2 receptor (HER-2) (AUC = 0.96). Differential expression analysis between ER+ and
ER– cancers identified over-expression of TTF1, LAF-4 and C-MYB (p ≤ 0.05), and between pCR vs non-pCRs, over-expression
of CXCL9, AREG, B-MYB and under-expression of ABCG2.
Conclusion: This study was an integrative analysis of copy number and gene expression using FFPE core biopsies and
showed that molecular marker data from FFPE tissues were consistent with those in previous studies using fresh-frozen
samples. FFPE tissue can provide reliable information and will be a useful tool in molecular marker studies.
Trial Registration: Trial registration number ISRCTN09184069 and registered retrospectively on 02/06/2010.
Keywords: Gene Expression, Copy Number, FFPE, Genomics, Breast Cancer, DASL, Molecular Inversion Probes Assay,
Oncoscan Array, Molecular Markers
* Correspondence: mahesh.iddawela@monash.edu
1Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way,
Cambridge CB2 0RE, UK
2Department of Oncology, University of Cambridge, Addenbrooke’s Hospital,
Hills Road, Cambridge, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Iddawela et al. BMC Genomics  (2017) 18:526 
DOI 10.1186/s12864-017-3867-3
Background
Breast cancer remains a major public health problem in
the western world, with a significant impact on mortality
and morbidity. Despite the considerable amount of re-
search that has been carried out, oestrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth
factor receptor 2 (HER-2) remain the only routinely used
molecular markers in breast cancer [1, 2]. Multiplex
markers are being introduced for particular clinical situ-
ation but these are currently expensive and not universally
helpful [3, 4]. Breast cancer is a heterogeneous disease and
large numbers of samples are needed to reliably character-
ise different subtypes with confidence [5, 6]. Unfortu-
nately, availability of FF (fresh frozen) tissues for
translational research are limited. However, on the other
hand, abundant supplies of FFPE (formalin-fixed paraffin-
embedded) tissues are readily available for use, provided
suitable assays are in place [7] .
One of the main problems associated with FFPE sam-
ples is that cellular RNA is degraded and therefore the
platforms must be adapted for analysis; this is one of the
challenges of using FFPE samples. Standard microarrays
used for FF samples are not suitable for analysis of FFPE
samples because conventional in-vitro transcription is
not amenable to analysis of degraded samples [8].
Two main technologies are employed for gene expres-
sion profiling using FFPE tissue: expression microarrays
using oligo-(dT) priming (Affymetrix and other custom-
made microarrays) and a combination of oligo-(dT)/ran-
dom hexamers together with gene-specific primers
utilised by the cDNA-mediated annealing, selection, ex-
tension and ligation (DASL) assay [9, 10]. In the DASL
assay, the expression of 502 genes is assessed, each using
three primers. Only a 40 bp sequence is required to de-
termine mRNA abundance, and hence this method is
generally suitable for the analysis of degraded FFPE sam-
ples [11]. Both of these platforms have been used for
gene expression profiling of FFPE core biopsy tissues.
Bibikova et al. showed that the DASL platform can be
used to assess gene expression profiles and evaluate
differentially-expressed genes in cancerous and normal
tissues [11]. Furthermore, we have shown reliable ex-
pression profiles can be generated using FFPE tissue
with profiles overlapping with those from FF tissues
[12]. DASL has been used to generate signatures of mo-
lecular markers associated with poor outcome in
prostate cancer [13], genes associated with poor out-
come in melanoma [14], and in oesophageal cancer [15].
Copy number alterations may have profound effects
on cancer development, and on progression and re-
sponse to treatment. Thus, characterisation of pivotal
changes and their molecular pathways in breast cancer
may have important clinical implications. Several well-
defined copy number alterations have been identified in
cancer, such as ERBB2 in breast cancer [16], N-MYC in
neuroblastoma [17, 18] and EGFR-1 in head and neck
tumours and gliomas [19–21], which have prognostic as
well as predictive implications.
Until recently, there has been uncertainty about the
value of FFPE tissue in clinical prognostic marker studies
because of technical problems such as difficulties in
DNA extraction, low quantities of extractable DNA, and
the problems associated with using such DNA owing to
degradation. Technological advances in DNA extraction
protocols and platforms used for genome-wide copy
number analysis (CNA) using DNA extracted from FFPE
tissue have progressed rapidly over the past few years
[22, 23]. Newer platforms used for CNA require less
DNA, rendering analysis of FFPE material a more realis-
tic and reliable technique.
The Molecular Inversion Probe (MIP) assay is a very
promising platform for CNA in both FF and FFPE mater-
ial [24, 25]. Degraded DNA can be used in this assay as it
only requires a 40-bp sequence for CNA, making it suit-
able for DNA analysis of FFPE material. This technique
has been used to define new copy number changes in
Ewing’s sarcomas and in childhood leukaemias [26, 27].
The reliability of this method has also been assessed using
samples obtained from several institutions. These data
suggest that this technology will be a useful tool for CNA
using FFPE tissue, and the low DNA requirement renders
it ideal for analysis of core biopsies of samples or in situa-
tions where only limited material is available.
Integrative analysis of both copy number and gene ex-
pression has been shown to be a valuable method for
identifying new molecular markers in cancer. In one of
the largest studies in breast cancer, Curtis et al. showed
that breast cancer can be divided into 10 subtypes using
integrative analysis [5]. Chin et al. further showed that
novel ER-negative breast cancers can be identified using
analysis of gene expression and copy number [28]. If
such analysis can be carried out on FFPE tissue, it will
enable the evaluation of larger numbers of clinical
samples and so lead to faster progress in translational re-
search [29]. This potential has a role in the discovery, as
well as the validation, of potential prognostic markers,
and as the samples are readily available it is a useful
source of material for translational research.
The previous study looked a the role of FFPE analysis
using the whole genome DASL assay and its role in gene
expression profiling of fresh and FFPE tissue [12].
In this study, profiling of copy number changes and
gene expression was carried out using the same FFPE
clinical samples. Routinely collected core biopsies were
used, to evaluate whether these assays can be used for
molecular marker studies. This study used the DASL
Cancer Panel Assay to evaluate the FFPE samples. To
the best of our knowledge this is the first genome-wide
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copy number and expression profiling study using FFPE
core biopsies from patients with large breast cancers
undergoing neoadjuvant chemotherapy (NAC).
Methods
Samples
In this study, 63 samples from patients with large locally
advanced breast cancer (LLABC) (T2 > 3 cm, T3 or 4,
N1,2) treated with NAC trial were used. The trial to
evaluate the safety and efficacy of weekly vs. 3 weekly
docetaxel (33.3 mg/m2 or 100 mg/m2) administration
after 3 weekly Adriamycin (60 mg/m2) and cyclophos-
phamide (100 mg/m2) for patients diagnosed with
LLABC in the period 1999–2002. All patients underwent
surgery 4 weeks post NAC, and a core biopsy was per-
formed in all patients prior to starting treatment and
patients consented to enter the neoadjuvant study. Fol-
lowing ethical approval, samples from these patients
were used for gene expression profiling and CNA.
Matched normal and tumour tissue taken at the time of
surgery were also used in this cohort.
The copy number analysis was undertaken using both
pre-NAC and normal tissues while gene expression was
only undertaken with pre-NAC samples only. The study
used core biopsy tumour tissue to evaluate these platforms
as this is the most readily available sample. Expression
analysis was undertaken using multiple replicates. While
for copy number analysis, both normal and cancer tissues
were used. The samples were evaluated for ER, PR and
HER-2 expression using IHC. The ER and PR were re-
ported as positive and negative and HER-2 expression re-
ported as 0 & 1(no expression), 2 (equivocal) and 3 (over-
expressed).
DNA extraction
Ten 10 μm sections from FFPE blocks were deparaffinised
with xylene, and DNA was extracted using the Qiagen
DNeasy Tissue kit (Qiagen®) according to the manufac-
turer’s protocol with several modifications. The modifica-
tions included an initial incubation at 95 °C for 15 min
(mins) in RTL buffer, followed by 5 mins. at room
temperature, before proteinase K treatment was per-
formed. Next, proteinase K was added every 24 h and
digested for 72 h at 56 °C in a thermomixer. The extracted
DNA was quantified using UV spectroscopy at 260 nm.
RNA extraction
Between five and eight 5-μm sections were cut from
each block of FFPE tissue, and then the samples were
deparaffinised with xylene and proteinase K treated for
14 h. Purification and DNase treatment – were per-
formed using a Roche High Pure RNA Purification Kit
(Roche Applied Sciences) and total RNA was stored
at −80 °C after extraction.
DNA and RNA quality control
The amount of DNA extracted was quantified using the
NanoDrop and PicoGreen assay. RNA was quantified
using the NanoDrop system, and the extent of degrad-
ation was measured using RT-qPCR for RPL13A mRNA
with the primers defined by Illumina [7].
cDNA-mediated annealing, selection and ligation (DASL)
assay and gene expression profiling
During the DASL assay, total RNA was converted to
cDNA in a reverse transcription reaction using biotinyl-
ated oligo-(dT) 18 and random hexamers. Pairs of query
oligonucleotides, with three unique pairs for each of 502
genes, were annealed to complementary sequences (~50
base pairs) flanking the specific cDNA target site. The
biotinylated cDNA was then bound to streptavidin
beads, and mis-hybridised and non-hybridised oligonu-
cleotides were washed away. Through a primer exten-
sion and ligation process, the biotinylated product was
generated, and this was then amplified by universal
fluorescent primers using conditions described below to
fluorescently label and amplify the template cDNA. The
5′ primers were labelled with Cy3 and Cy5 fluorogenic
dyes, respectively, while the 3′ primer contained the
address sequence that is complementary to a secondary
address sequence located on array (SAM). The amplified
cDNA was then denatured and hybridised to the SAM
at 60 °C in a hybridisation oven with an oscillating table.
Following overnight hybridisation, the array was washed
and then scanned using the BeadArray reader (Illu-
mina™). Image processing and intensity data files were
analysed using BeadStudio software.
The probes used for the DASL assay were sourced
from a cancer panel which consisted of 502 genes gener-
ated using 10 publically available data sets (http://
www.gtbiotech.com.tw/pdf/DASL%20Assay%20-
Work%20Flow.pdf). The selection was based on their
frequency of citation in the lists and also their associ-
ation with cancer.
Allelic composition analysis: molecular inversion probe
(MIP) assay
DNA (2.35 μl) was mixed with 1.1 μl of 53 K probe pool
(200 amol/μl/probe) and placed in a 96-well plate in ice.
The reaction mixture was incubated at 20 °C for 4 mins,
and 95 °C for 5 mins, then 58 °C overnight. Next, 13 ml
of a second enzyme mix and buffer were added. The
MIPs were circularised by the addition of 4 μl of dinu-
cleotides (dATP with dTTP, dCTP and dGTP) and
mixed at 58 °C for 10 mins. The non-circularised probes
and genomic DNA were eliminated by the addition of
4 μl of exonuclease mix and incubated at 37 °C for 15
mins, and then heat treated. The circularised probes
were linearised by adding cleavage enzyme mix at 37 °C
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for 15 mins, then subjected to universal primer amplifi-
cation for 18 cycles at 95 °C for 20 s, 64 °C for 40 s, and
72 °C for 10 s. For the labelling reaction, products were
further amplified with labelled primers for 10 ten cycles,
and then subjected to cleavage by a digestion enzyme
mix at 37 °C for 2 h. The products were mixed with a
hybridisation cocktail, denatured and hybridised to Affy-
metrix Universal 70 K Tag arrays at 39 °C for 16 h (two
arrays per sample). After overnight hybridisation, arrays
were washed on Affymetrix GeneChip Fluidics Station
450 and stained by streptavidin-phycoerythrin (SAPE) at
5 mg/ml (Invitrogen).
Data analysis
The data from the MIP arrays were normalized using a
2pSE structuring element, which has been established as
the best method for normalising MIP data [30]. Two dif-
ferent algorithms were used for copy number analysis.
First, the data was then segmented using the circular bin-
ary segmentation (CBS) algorithm [31]. This algorithm
splits the data into segments of equal copy number. A
more refined analysis was done using the reverse jump
array comparative genomic hybridisation (RJaCGH) algo-
rithm, that fits a non-homogeneous hidden Markov model
using reversible jump Markov chain Monte Carlo compu-
tation, and that takes into account model uncertainty
using Bayesian model averaging [32, 33]. This method es-
timates the probability that a region/gene has a copy num-
ber alteration (rather than a p value or smoothed mean)
and is useful in both basic and clinical applications. This
algorithm also takes into account the distance between
the probes, and is for this platform where there is an un-
even distribution of markers on each chromosome. For
example, in densely covered areas, the copy number of
one probe is indicative of the copy number throughout
the whole area. In contrast, in poorly covered areas where
the probes are further apart, it is possible that copy num-
ber alterations will have occurred, but not be detected, so
each probe provides much less information about the state
of the neighbouring probes. Therefore, the distance be-
tween the probes needs careful consideration to ensure
that the data provided by the consecutive probes was re-
corded accurately. This algorithm has the ability to assess
data for each chromosome or on a genome–wide basis.
Agglomerative hierarchical clustering was carried out
using the base R package function hclust with Ward’s
method. This allows compact clusters to be generated
from the data and uses an analysis of variance approach to
determine the distance between the clusters [34]. The
smaller the increase in the sum of the within-group sum
of squares, when two clusters are merged, the closer the
two clusters. The within-group sum of squares was de-
fined as the sum of squares of the distance between all ob-
jects in the cluster and the mean centroid of the cluster.
Robustness of the cluster was assessed using the R
package pvclust method [35]. This method assesses the
uncertainty in hierarchical clustering by calculating
quantiles called a p-value via multi-scale bootstrap re-
sampling. Gene ontology assessment was carried out for
the data using the Bioconductor package GOstats [36].
Quality control checks were carried out on the extracted
data to identify any spatial effects or problems with
probes. For the initial analysis, the data were quantile nor-
malised, and hierarchical clustering was undertaken to as-
sess the robustness of the platform. Hierarchical clustering
is a robust method used to assess the relationship between
samples. To assess robustness, a more detailed analysis of
the probes and replicate arrays was carried out with the
aim of further removing any noise. The MA and XY plots
for the red and green channels were used to assess the
array quality between the replicates, and those that did
not agree with the replicates were removed.
For gene expression profiling, the majority of samples
were assessed with multiple replicates. Pearson’s correl-
ation coefficient (r) was used to assess the reproducibility
of the probes between replicates, and where r2 < 0.7 these
data were excluded. The genes involved were initially se-
lected as they passed the stringent criteria described. The
average red and green signals of these probes were calcu-
lated and the data were quantile normalised. A subsequent
analysis of the data was then undertaken.
Results
Patient characteristics
Forty-three of the 63 (68%) patients treated in the NAC
had sufficient DNA following extraction for analysis,
while RNA was extracted from 52 of 63 (82%) FFPE core
biopsies. For CNA, 43 samples were used, while 46 sam-
ples were used for gene expression analysis. Clinical in-
formation and the tumour characteristics of the patients
in this cohort are shown in Table 1 (Additional file 1).
The mean age of the patients was 50 years (range 32–
70), 33 (72%) of the tumours were T2, while 27 (58%)
were grade 3. Of the patients, 30 (65%) had ER positive
and a pCR was found in 30% (14/46) of the patients fol-
lowing NAC.
Correlation between IHC, gene expression and copy
numbers
The median DNA yield per sample was 325 ng (range
198–2000) while the RNA yield was 1800 ng (range
114–3696). The matched normal tissues from a cohort
of samples were used for normalising copy number data.
Six of the 43 tumours exhibited gains or amplification in
HER-2 when assessed using the MIP assay (14%). When
correlated with assessment by immunohistochemistry
(IHC), five samples had an IHC score of 3+ (83%), a fur-
ther three samples had an IHC score of 2 + .
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Gene expression, as assessed by the DASL assay, was
compared with IHC to assess the reliability of the plat-
form. The IHC scores for ER, PR, HER-2 and BCL2 pro-
teins were compared with DASL gene expression results.
Gene expression was dichotomised using a median cut-
off, and an area under the curve (AUC) was generated to
compare the two platforms (Table 2).
Gene expression of ESR1 was assessed using the three
probes of the DASL assay, compared with the IHC ER-
positive and -negative status (Fig. 1). As shown, ER-
positive tumours exhibited elevated ESR1 expression com-
pared with ER-negative cancers, and the difference was
statistically significant (linear regression p value = 0.023).
The AUC analysis comparing the two platforms exhibited
robust overlap with values of 0.77–0.8 (p = 0.002).
However, the correlation between the two platforms was
in the range of 0.4–0.8, depending on the probes used.
The probe-specific variation in the signal is very clear as
the ESR1_3 had a lower signal compared with the other
two probes and, as shown, this also has a lower AUC. De-
tailed analysis of the primer binding sites on the ESR1
gene showed that the probe with a lower AUC binds to a
site closer to the 5′-UTR (un-translated region) than the
other two probes, with a high gene expression signal
(Additional file 2).
A similar comparison was carried out for HER-2,
where a significant difference in gene expression was
found according to the HER-2 status assessed by IHC,
with the cancers classed as IHC 3+ having a greater ex-
pression value (p = 0.022, Fig. 1). The AUC was 0.91–
0.95 using this probe (p < 0.001) and the correlation was
0.75–0.81. When this analysis was used to assess PGR
and BCL2 status, there was again a difference in gene
expression between those classed as positive and those
classed as negative (linear regression p = 0.0002 for PGR
and p = 0.01 for BCL2). The AUC for these two genes
was >0.70 (p < 0.05) for all probes except for one of the
BCL2 probes, and the correlation was also significant for
all probes except this BCL2 probe (Table 2).
Copy number changes in breast cancer
The regions with the highest frequency of gains
(>30%) comprised 1q (42%), 8q (40%), 11q (40%), 17q
(32%) and 20q (35%) (Fig. 2). A high frequency of
gains was also observed in smaller regions of 5p15.31
(45%), 5q15.2 (51%), 5q23.1 (53%), 12q24.22 (49%)
and 14q21.3 (51%). The regions identified as having
the highest frequency of loss comprised 4p (34%), 4q
(34%), 6q (43%), 8p (30%), 13q (30%), 16q (30%) and
18q (35%) (Fig. 2) (Additional file 3).
The copy number data were analysed using clustering
methods to identify any robust groups in this cohort.
Unsupervised clustering showed that there were two dis-
tinct groups – 1 and 2 – with distinct pathological fea-
tures. In Group 1, 83% of the cancers (15/18) were ER-
positive tumours. Group 2 was more heterogeneous,
with 10 ER-positive and 9 ER-negative tumours (Chi
squared test, p value = 0.001). The robustness of the
Table 1 Characteristics of the patients used for expression and
copy number analysis
Mean Age (Years) 50
Range 32–70
Tumour Type
Ductal Carcinoma 44 (96%)
Lobular Carcinoma 2 (4%)
Tumour Grade
1 3 (7%)
2 16 (35%)
3 27 (58%)
Tumour Stage (Breast)
T1 5 (11%)
T2 33 (72%)
T3 6 (13%)
T4 2 (4%)
Oestrogen Receptor
Positive 30 (65%)
Negative 16 (35%)
Pathological Response
Pathological Complete Response (pCR) 14 (30%)
No Pathological Complete Response (Non-pCR) 32 (70%)
Table 2 The AUC for each DASL probe compared with IHC and the correlation between gene expression assessed using DASL and
IHC score (*statistically significant p < 0.05, **p < 0.0001)
Marker AUC for each probe Correlation for each probe
1 2 3 1 2 3
Oestrogen receptor 0.95** 0.83* 0.75* 0.77** 0.57** 0.44*
Epidermal growth factor receptor −2 0.96** 0.96** 0.94** 0.75** 0.75** 0.81**
Progesterone receptor 0.72* 0.90* 0.90* 0.36* 0.66* 0.64*
BCL2 expression 0.74* 0.8* 0.46 0.40* 0.60* 0.11
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clusters was assessed using the pv-clust software pack-
age, which provides an approximate unbiased p value
and bootstrapping probability. This showed that the
clusters are distinct with defined features.
The effect of copy number gains of known oncogenes
such as ERBB2, CCND1 and C-MYC in breast cancer,
was used to assess the robustness of the platform. Of the
breast cancers assessed, there were gains in HER-2 in
33%, CCND1 in 32%, and C-MYC in 39%. The survival
analysis of the patients with these gains showed that
HER-2 amplification and C-MYC gain was associated
with poor overall survival and that the frequency of
these gene CNA are similar to that described in other
breast cancer studies.
Description of gains and losses and correlation with
pathology
The ER-positive tumours had the highest frequency of
gains in 1q and 8q, while there were focal gains in 11q11
and 20q13. In ER-negative tumours, 11p and 17q had
the highest frequency of gain.
When grade 3 and 1 tumours were compared, 8q23.3–
q24.11 (49% vs 17%), 8q24.11 (48% vs 16%) and 8q24.21
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Fig. 1 Box plot showing gene expression in cancers according to IHC status and the Area Under the Curve (AUC) for each of the probes for each
marker (number of samples). a & b = oestrogen receptor expression (positive = 30 & negative = 16), (c & d) = ERBB-2 expression 0 (15), 1 (2),2 (5)
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(43% vs 9%) were found to be more common in grade 3
lesions, while gains in 1q21.1–q21.2 (55% vs 29%),
1q24.1 (54% vs 25%), 1q21.2–21.3 (54% vs 26%), and
1q22 (55% vs 27%) were found to be more common in
grade 1 tumours. These changes were statistically signifi-
cant following multiple testing (FDR < 0.05). Loss at 16q
was seen in 40% of the grade 1 tumours compared with
18% of the grade 3 tumours.
When CNA and responses to NAC were assessed,
gains were frequent in 1q (55%), 8q (40%) and 17q (40%)
among pCR tumours, while 11q11 gain was more fre-
quent among the non-pCR tumours. The data also
showed that 8p (40%) and 13q (70%) losses were more
common among the pCR tumours, but none of these
regions were statistically significant.
Common regions of alteration associated with poor overall
survival comprised gains in 11q13 (62%), 8q24.21 (54%),
8q24.22 (54%) and 20q13.13 (47%) (p < 0.1). The region most
frequently gained in patients with a good overall survival was
1q. There were several regions of 1q and these were: 1q31, 3
(39%), 1q32.2 (39%), 1q41 (39%) and 1q31 (39%).
Gene expression profiling of the pre-treatment core
biopsies – differential expression analysis
Differential gene expression analysis was carried out to
assess overlap with published data, and which would act
as a validation of the role of the assay. Differentially
expressed genes between the 30 ER-positive and 16 ER-
negative cancers were assessed and, as shown, all the
three ESR1 probes were classified as highly expressed in
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Fig. 2 Chromosomal plot showing copy number aberrations in all tumours analysed in the study (X-axis- chromosome number 1-X & Y axis frequency
of alteration, Gains-green and Losses-red)
Table 3 Top 10 differentially expressed genes (each probe) between oestrogen receptor positive and negative cancers
FDR Log-Fold Change Genes Gene name
1.90E-07 1.992 TFF1 TREFOIL FACTOR 1 (BREAST CANCER, OESTROGEN-INDUCIBLE
SEQUENCE EXPRESSED IN)
7.13E-06 1.511 ESR1 OESTROGEN RECEPTOR 1
6.90E-05 1.568 ESR1 OESTROGEN RECEPTOR 1
1.00E-03 1.012 LAF4 NUCLEAR PROTEIN RELATED TO AF4
1.00E-03 1.299 ESR1 OESTROGEN RECEPTOR 1
2.00E-03 0.780 C-MYB V-MYB MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOGUE (AVIAN)
3.00E-03 1.464 AREG AMPHIREGULIN (SCHWANNOMA-DERIVED GROWTH FACTOR)
3.00E-02 −0.964 CD44 CD44 ANTIGEN (INDIAN BLOOD GROUP)
3.00E-02 0.765 LAF4 NUCLEAR PROTEIN RELATED TO AF4
3.50E-02 0.800 ERBB4 V-ERB-A ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOGUE
4 (AVIAN)
Well-characterised ER regulated genes are shown in bold and note each ESR1
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ER-positive cancers and were significant on multiple testing
(FDR p ≤ 0.001) (Table 3) (Additional files 4, 5, 6, 7).
This analysis also showed that other oestrogen-
regulated genes such as TFF1, PGR and C-MYB were
also present in the top 25 genes classified as highly dif-
ferentially expressed (FDR p < 0.05). LAF4 and AREG
showed high expression in ER-positive breast cancers,
and all three transcripts showed high expression among
ER-positive breast cancers. Due to small the sample size
these changes could be biologically not significant and
need further validation.
Grade 1 and 3 tumours were also assessed to identify
those genes that were differentially expressed between
the high-grade and low-grade tumours. As shown below,
BIRC5, ERBB4, SOD1, ARHGDIB and CDC25B were the
top 4 differentially expressed genes (Table 4). All the
genes, apart from ERBB4, were over-expressed in grade
3 tumours compared with grade 1 tumours, and all three
ERBB4 transcripts were present in the top 25 genes.
Although gene expression changes are statistically
significant, some of the log fold changes are small and
might not contribute to meaningful biological or physio-
logical changes. This is especially the case when limited
number of samples are used, hence both further validation
and functional analysis is important for confirming the
role of any potential markers in any study such as this.
The pCR rate following NAC study was 26% (12/46)
and the expression profiles of these samples were used to
assess differentially expressed genes between patients
whose tumours had a pCR or non-pCR with NAC. The
top three differentially expressed genes were CXCL9,
ARHA and ARHGDIB, but this observation was not statis-
tically significant on multiple testing (p < 0.11, Table 5).
All three ARHGDIB alternate transcripts exhibited ele-
vated expression in patients with pCR. There was lower
expression of the multi-drug resistant transporter, ABCG2
gene, in those tumours with a pCR following NAC.
Gene ontology assessment of the top 50 differentially
over-expressed genes indicated that the two most
significantly-enriched GO categories were regulators of bio-
logical processes (61% of which were genes such as MYB,
ARHDIB and CDK9) and cellular metabolic processes (61%
of which were genes such asMAPK14, SKIL and FGFR3).
Gene expression and copy number changes
The best performing 308 probes were correlated with
copy number data. Overall, when all the reliable probe
expression and copy number were compared, 25%
probes had a Pearson correlation >0.26 and 50% more
than >0.14. For certain probes, such as those targeting
ERBB2, CCND1, GRB7, and BIRC5, there was good con-
cordance observed between gene expression and locus
copy number (Table 6). Nevertheless, in some instances,
there was diminished correlation between detected copy
number and quantified mRNA expression, as seen with
probes 1 and 2 for the FGF3 gene (FGF-P1 and FGF-P3).
Results for the well-characterised tumour suppressor
gene CDH1 indicated a correlation of 0.4, while TOP2A
had a correlation of 0.44. A strong correlation was also
found between copy number and mRNA expression for
other genes in regions such as 11q13 (CCD1), 20q13
(B-MYB) and 17q12 (ERBB2).
Genes associated with a pCR and their relationship be-
tween copy number and gene expression were evaluated,
TNFAIP1 was revealed as a locus that demonstrated a
very high correlation between copy number and expres-
sion (r = 0.99) (Table 7). None of the genes associated
with pCR were statistically significant. Of the other
genes, two of the three HER-2 transcripts exhibited
strong correlations between expression and copy num-
ber and were further associated with pCR. The genes
associated with ER-negative status and with high copy
number and gene expression ratios comprised ERBB2,
GRB2, STAT3, CCND1, MUC1 and FGFR3.
Table 4 Table showing the top 10 differentially expressed genes (each probe) between grade 1 and grade 3 tumours
FDR Log-Fold Change Genes Gene name
0.186 0.271 BIRC5 BACULOVIRAL IAP REPEAT-CONTAINING 5 (SURVIVIN)
0.186 −0.337 ERBB4 V-ERB-A ERYTHROBLASTIC LEUKAEMIA VIRAL ONCOGENE HOMOLOGUE
4 (AVIAN)
0.216 1.149 SOD1 SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC LATERAL SCLEROSIS
1 (ADULT))
0.247 0.723 ARHGDIB RHO GDP DISSOCIATION INHIBITOR (GDI) BETA
0.247 0.622 CDC25B CELL DIVISION CYCLE 25B
0.247 0.417 CXCL9 CHEMOKINE (C-X-C MOTIF) LIGAND 9
0.247 0.964 GRB7 GROWTH FACTOR RECEPTOR-BOUND PROTEIN 7
0.247 1.156 HIF1A HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT (BASIC HELIX-LOOP-HELIX
TRANSCRIPTION FACTOR)
0.247 1.117 B-MYB V-MYB MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOGUE (AVIAN)-LIKE 2
0.247 −0.348 PGR PROGESTERONE RECEPTOR
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Discussion
This study has revealed that FFPE core biopsies can be
used for integrative analysis of gene expression and copy
number in breast cancer. The majority of core biopsies
from patients could be used for gene expression analysis.
Our findings have significant implications for the wider
application of FFPE tissue in translational research and
clinical use [2, 37, 38].
It is important to compare results from these new
platforms with other established methods for molecular
marker analysis, such as IHC. When gene expression
was compared with IHC for routine markers, concord-
ance was significant (ER; p = 0.002, HER-2; p < 0.001,
and PR; p = 0.0002). Very few studies have attempted to
compare gene expression profiling with IHC. Gong et al.
used gene expression profiles of FF tissue to determine
ESR1 and HER-2 status among a cohort of 495 breast
cancer patients. The data from 195 tumours were used
to define the cut-off, and the accuracy of the cut-off was
assessed in 300 samples from two further series. This re-
vealed that Spearman’s correlation coefficient ranged
from 0.62 to 0.77. The correlation coefficients for ESR-1
and HER-2 were 0.77 and 0.81, respectively, for the best-
performing probes using the DASL assay in these
samples. This is very encouraging, and by using these
probes, ER and HER-2 status can be reliably determined.
Abramovitz et al. also showed that there was high con-
cordance between ER, PR and HER-2 IHC and DASL
(p < 0.01), with significant differences between positive
and negative tumours [39]. This degree of agreement is
very similar to the extent of concordance observed when
ER and HER-2 FISH (fluorescence in situ hybridisation)
assessments are carried out on the same samples in dif-
ferent laboratories [40]. These data are of interest as
they suggest that DASL is a useful tool for molecular
marker analysis.
We identified a high correlation between IHC for
ERBB2 and MIP amplification of FFPE breast cancer spec-
imen’s 17q13 loci, with 83% concordance between the two
platforms. The concordance was 73% in Andre et al.’s
Table 5 Table showing differentially expressed genes (each probe) between pathological complete responders (pCR) and those
with no pathological complete response (non-pCR)
FDR Log-Fold Change Genes Gene name
0.087 0.911 CXCL9 CHEMOKINE (C-X-C MOTIF) LIGAND 9
0.104 0.586 ARHA RAS HOMOLOGUE GENE FAMILY, MEMBER A
0.104 0.700 ARHGDIB RHO GDP DISSOCIATION INHIBITOR (GDI) BETA
0.104 0.925 BCL3 B-CELL CLL/LYMPHOMA 3
0.104 0.665 CD44 CD44 ANTIGEN (INDIAN BLOOD GROUP)
0.104 0.912 CDKN1B CYCLIN-DEPENDENT KINASE INHIBITOR 1B (P27, KIP1)
0.104 0.638 CSF1R COLONY STIMULATING FACTOR 1 RECEPTOR, FORMERLY
MCDONOUGH FELINE SARCOMA VIRAL (V-FMS) ONCOGENE
HOMOLOGUE
0.104 0.742 DCN DECORIN
0.104 0.783 EGR1 EARLY GROWTH RESPONSE 1
0.104 0.600 LCK LYMPHOCYTE-SPECIFIC PROTEIN TYROSINE KINASE
Table 6 Correlation between gene expression and copy number
for the robust probes used in the DASL assay (P1–3-identity of the
probes used to assess each gene in the DASL assay) (Correlation
between copy number and gene expression: 25% of probes >0.26
and 50% probes >0.14)
Gene name and
DASL probe number
Correlation between
expression and copy number
95% Confidence
Interval
ESR1-P2 0.483 [0.161–0.712]
JUND-P1 0.490 [0.06–0.766]
MUC1-P2 0.497 [0.144–0.738]
BIRC5-P1 0.500 [0.17–0.729]
RAN-P1 0.503 [0.152–0.741]
RELA-P1 0.525 [0.172–0.758]
BIRC5-P2 0.527 [0.205–0.745]
COMT-P1 0.556 [−0.026–0.857]
FGFR1-P1 0.575 [0.283–0.769]
GRB7-P1 0.585 [0.192–0.816]
ERBB2-P1 0.733 [0.43–0.888]
CCND1-P1 0.773 [0.512–0.903]
HER-2-P2 0.800 [0.553–0.918]
Table 7 Genes where there is a high correlation between copy
number, expression and clinical feature
Clinical characteristic Genes where copy number and
expression correlation >0.75
Pathological complete response TNFAIP1, JUND, HER-2, NFKBIA, PDGF,
IL13, CCND1
Genes associated with ER-
negative status
GRB2, HER-2, STAT3, CCND1, MUC1,
FGFR3
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group of 68 patients and 100% in the 61 patients in Pierga
et al.’s series. Both these studies used FF DNA, which fur-
ther confirms the robustness of the MIP assays [41, 42].
Nucleic acid base modifications and cross-linking
occur following formalin fixation, rendering intact nu-
cleic acid extraction difficult from these tissues [43].
Many groups have extracted DNA from FFPE tissue
blocks and have shown that considerably less DNA can
be extracted from FFPE tissues than from FF samples,
and this limits its application [44]. Jacobs et al. and
Oosting et al. used FFPE DNA from tumour for CNA
employing the Affymetrix 500 K array and llumina SNP
BeadChip. These platforms require 0.25–1 μg of DNA to
generate genome-wide copy number data [45, 46]. The
results from these investigations showed that the major-
ity of core biopsy samples contain sufficient DNA for
analysis using the Affymetrix 500 K array, but that only
60% of the samples in these studies could be analysed
using the Illumina platform. These analyses used FFPE
tissue blocks from which to extract DNA, but there is a
considerable amount of material available from the ini-
tial diagnostic core biopsies in a majority of cases.
The MIP assay is well suited to the analysis of FFPE
DNA as it only requires an intact 40-bp sequence
and <40 ng of DNA as template [24]. Limitations of
other platforms include a requirement for high DNA
quantity and quality, and a high output of DNA fol-
lowing amplification, which cannot be achieved using
PCR of FFPE samples, Furthermore, many samples
exhibit PCR amplification bias due to short template
fragment size [47].
Recurrent gains in chromosomes 1q, 8q, 11q, 17q and
20 q and losses in 6q, 8p, 13q and 16q were frequently
observed in this study. These identified copy number ab-
errations were similar to those described in previous
studies where genome-wide changes were analysed by
chromosomal CGH [48] and aCGH [23, 41, 49–51]. The
majority of copy number studies to date have been car-
ried out using FF samples and have employed platforms
requiring high DNA input. Most studies have identified
8q, 11q, 17q and 20q as the most frequently gained re-
gions. Andre et al. described gains in 8q (58%) and 1q
(55%) and losses in 8p (51%) and 13q (41%) as some of
the commonest copy number changes using FF DNA,
which concurs with our data, whereas gains in 11q, 17q
and 20q were not frequent in their data set [41]. The
study by Nessling et al. is one of the published studies
where locus copy number changes in breast cancer using
FFPE tissue were examined. Our data presented here
overlap well with their findings. The authors of that
study used a matrix-CGH platform containing 422 auto-
somal markers to profile 31 tumours, and it is encour-
aging that comparable changes can be identified in FFPE
tissue using different platforms, as this suggests that the
DNA from such samples is a reliable, readily obtained
source for DNA analysis.
Gains in 1q and 8q and losses in 16q were observed in
ER-positive cancers, as described by others, while ER-nega-
tive tumours were more likely to over-express 17q loci –
consistent with the observations of other groups [52].
This study was a feasibility study investigating the role
of the integrative analysis of core biopsies for copy num-
ber and gene expression profiling and did not aim to dis-
cover new molecular markers. Even so, there were several
regions in 1q, 8q and 20q that showed alterations in breast
cancer with a pCR compared with those without pCR;
these differences were not statistically significant. Using
106 fresh tumours, Andre et al. showed that regions in 3q,
6p, 11p, 11q, 18q and 19q were significantly altered in
breast cancers showing pCR, compared with non–re-
sponders, but this did not reach statistical significance
when adjusted for multiple testing (FDR = 0.59) [41].
This study used core biopsy tissue for RNA and DNA
extraction and this data confirms that this is a resource
that is suitable for molecular marker studies. In a large
population-based study, tissue cores from melanoma bi-
opsies were used for profiling using the DASL assay;
only 1.4% of the samples failed to yield sufficient RNA
using this approach. This is dependent on the age of the
sample as older tissue blocks have lower yields and
higher level of degradation [53].
Differential expression analysis was aimed at validating
the platform further and identifying potential new mo-
lecular markers. Differential expression analysis between
ER-positive and -negative tumours revealed that all three
alternatively-spliced mRNA transcripts of ESR1 are (with
TFF1) represented in the top four differentially-
expressed genes. This is highly significant as we would
expect the main discriminator to be ESR1 between these
cohorts. TFF1 is also a well-characterised oestrogen-
regulated gene and has been shown to be upregulated in
ER-positive breast cancers in multiple data sets [54, 55].
A proportion of gene expressions can be accounted for
by underlying copy number alterations. Thus, identification
of oncogenes that are amplified or lost may lead to the dis-
covery of potential new molecular markers [56]. CNA will
help to reveal which amplicons or regions are frequently
altered in cancers. Subsequently, genes at these loci can be
studied in more detail to characterise potential oncogenes
or tumour suppressor genes. In addition, a high correlation
was observed between copy number and gene expression
in regions commonly amplified in breast cancer, such as
20q13 (B-MYB), 17q (HER-2) and 11q (CCND1).
There was a good correlation between copy number
and expression among the pCRs for several genes in-
cluding HER-2, CCND1, TNFAIP1 and JUND. This is a
well-established relationship as many studies have shown
that HER-2 positivity is associated with higher response
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rates to NAC [57]. Penault-Llorca et al. observed that
CCND1 positivity with IHC was increased following
neoadjuvant chemotherapy, but they were unable to
show a correlation with response to chemotherapy [58].
CCND1 is a frequently amplified gene in breast cancer
and has been previously shown to be associated with im-
proved disease-free and overall survival.
The genes assessed as part of the DASL cancer panel
assay consisted of 502 genes derived from various pub-
lished data sets where gene selection is biased towards
haematological malignancies. This is not an ideal setting
for ‘class discovery’ in breast cancer but represents a use-
ful platform for an initial pilot study [59]. The unbiased,
DASL WG assay – where all transcripts are assessed – is
a superior platform, but was not available at the start of
this study. This is a ‘bottom-up’ model for molecular
marker studies as it only assesses a limited number of
markers, although this approach has been successfully
used in other studies [60]. For example, a similar approach
was adopted by Paik et al. for deriving their Recurrence
Score™, where they used an initial list of 250 genes from
published studies; this was then used to arrive at their final
selection of 16 genes [38]. A recent consensus statement
on FFPE analysis suggested initially using a targeted pilot
project to assess the robustness of the platform.
In our study, only a relatively small number of samples
were investigated, and therefore it has a constraining
power in detecting genes of significant effect, as shown
in many other studies of similar size [61–63]. Neverthe-
less, ours was one of the first analyses of an FFPE plat-
form to be carried out for breast cancer, to assess the
platform and robustness compared with an IHC ap-
proach, using either DASL or any other technology for
gene expression profiling employing FFPE tissue.
The results obtained using the DASL assay are com-
parable with those for IHC and the DASL assay has the
potential to assess large numbers of markers, hence
enabling large numbers of samples to be evaluated for
potential molecular markers. This is particularly valuable
in cancers where there is limited availability of fresh tis-
sue. In our study, core biopsy samples were successfully
used for CNA using an MIP assay. This shows that both
the DASL and the MIP assays provide a valuable tool for
molecular marker studies in cancer.
Conclusion
Integrated genomic and transcriptomic analysis of FFPE
samples will allow rapid progress in molecular marker
identification in cancer research. This is one of the first
studies, to have shown the use of FFPE samples to assess
gene expression and copy number analysis. The expres-
sion profiles from FFPE samples correlated with those
from FF samples. Therefore, FFPE samples can be more
readily used for translational research in the future.
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